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ABSTRACT
OBJECTIVE: The objective of this selective EBM review is to determine whether or not “In
adult patients with Obsessive Compulsive Disorder (OCD), is the amino acid N-Acetyl Cysteine
(NAC) effective in reducing severity of OCD?”
STUDY DESIGN: Review of three English language primary studies, published between 20152017.
DATA SOURCES: Three randomized controlled trials (RCTs) were found using PubMed-NCBI.
These studies analyzed the effectiveness in reducing the severity of OCD in adults with OCD.
OUTCOME MEASURED: The main outcome measured was a reduction of OCD severity after
taking N-Acetyl Cysteine. Outcomes were measured using the Yale-Brown Obsessive
Compulsive Scale (Y-BOCS). Participants answered a 67 part questionnaire about their everyday
habits. From the questionnaire, the interviewer generated a list of target OCD symptoms. The
target symptoms were then used in 19 interview style questions asking about the severity of each
symptom. The severity of those symptoms range from 0-4, with 4 being the highest severity.
Questions 1-10 were added together for a Y-BOCS final score, based on the patient’s responses.
RESULTS: There was an overall reduction of symptoms from the beginning to end of each trial.
However, the placebo group had a similar reduction in symptoms, which made the results
statistically insignificant. In the study conducted by Costa et al. 6 of 16 patients in the NAC
group versus 5 of 19 patients in the control group had a significant reduction in Y-BOCS score
(P=0.40). In the results of the study by Paydray et al. 11 of 22 in the NAC group and 8 of 22 in
the control group had a significant reduction in Y-BOCS score (P=0.54). In the study conducted
by Sarris et al. 4 of 20 patients in the NAC group versus 4 of 15 in the control group had a
significant reduction in Y-BOCS score (P=0.15).
CONCLUSION: The results of the RCTs remain inconclusive as to whether NAC is an effective
medication for reducing the severity of OCD in adults. NAC as an alternative treatment to
current medications for OCD remains affordable and tolerable, indicating further research is
needed for its efficacy.
KEY WORDS: Obsessive Compulsive Disorder, N-acetylcysteine
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INTRODUCTION
Obsessive Compulsive Disorder (OCD) is a psychiatric disorder in which a person has
intrusive thoughts, ideas, or urges (obsessions) that can force him/her to perform repetitive
activities or rituals (compulsions) to relieve the sense of anxiety associated with those thoughts,
ideas, or urges.1-3 To be diagnosed with OCD, a person can have obsessions, compulsions, or
both, and his/her symptoms are not attributable to another disorder and must cause clinically
significant stress, according to the DSM-V.3 While symptoms can vary, OCD can be categorized
into four characteristic groups: cleaning, symmetry, forbidden or taboo thoughts, and harm.3
Cleaning encompasses the fear of contamination, which causes the person to have sanitation
rituals such as washing his/her hands multiple times. Symmetry comprises of repeating, ordering,
and counting compulsions.3 Forbidden or taboo thoughts involve beliefs that are not acceptable
to society such as aggressive or sexual obsessions and compulsions. 3 Harm revolves around
thoughts or images about others or himself/herself getting hurt; he/she will continually verify
that harm won’t occur.3 Quality of life and psychosocial performance are severely reduced in
persons with OCD. Anxiety and task completion are time consuming and debilitating,
demanding more than an hour of time per day.1,3
OCD affects approximately 2.3% of the U.S. population as a lifelong disorder, while
1.3% of the U.S. population is affected for a 12-month period.3 Males are more affected in
adolescence while females are more affected as adults.3 Individuals with existing disorders such
as schizophrenia, schizoaffective, Tourette’s, bipolar, or eating disorders have a higher
prevalence of OCD.3 Seventy-six percent of people with OCD have a comorbid anxiety
disorder.3
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While the current cost is unknown, in 1990 OCD was estimated to cost 8.4 billion
dollars.4 This includes direct costs of services and medications, but also indirect costs such as
loss of productivity and unemployment. In 1990 the estimated indirect costs totaled 74%, or 6.2
billion dollars, of the total yearly cost of OCD.5 In 2005 the total cost increased to 10.6 billion
dollars, with indirect costs not calculated.4 In a nationwide survey conducted between 2003 and
2010, 728,644 healthcare visits per year were by people diagnosed with OCD.6 Visits varied
from medication changes to psychotherapy, with a range of psychiatrists, primary care
physicians, and other specialties treating these patients.6
OCD is believed to be caused by a combination of genetic and environmental factors.
There is increased incidence throughout families. Factors such as trauma, major life events,
premenstrual periods, and postpartum periods correlate to patients with new diagnoses or
exacerbations of OCD.3 Research suggests that OCD involves the cortico-striato-thalamocortical (CSTC) circuit, the orbitofrontal cortex, and the ventromedial striatum within the brain.3
In these regions, there is dysregulation and increased levels of the neurotransmitter, glutamate.3
Excess glutamate causes hyperactivity and oxidative stress which correlates to symptoms found
in OCD patients.3 OCD typically has a gradual onset in the third decade of life and can consist of
wide range of obsessions and/or compulsions. Standard methods used to treat OCD include
selective serotonin reuptake inhibitors (SSRIs), clomipramine, cognitive behavioral therapy, and
atypical antipsychotics.1,2,7 Other medications include riluzole, memantine, topiramate,
lamotrigine, and NAC.2
NAC is a prodrug of cysteine that acts to modulate the glutamate-cysteine antiporter
within the CSTC circuit, orbitofrontal cortex, and the ventromedial striatum.8 As mentioned
above, OCD patients have been found to have excess glutamate within glial cells.8,9 By providing
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NAC, extracellular cysteine levels are increased, allowing the antiporter on glial cells to
exchange extracellular cysteine for intracellular glutamate.1 The excess glutamate then leaves the
cell and binds with inhibitory receptors on neighboring neurons, preventing synaptic release of
glutamate.9 A glutamate decrease within glial cells indirectly reduces oxidative stress these cells
undergo, thereby reducing cellular damage.8,9 Additionally, cysteine is a component of
glutathione, an antioxidant that directly removes reactive oxygen species and nitrogen species
from glial and neuronal cells.1,9 By providing the prodrug, NAC, levels of glutathione are
increased, allowing for increased removal of reactive oxygen species that would otherwise
damage the cells.1,8,9
There is no cure for patients with OCD. However, there are multiple therapies aimed at
reducing the symptoms the patients experience. This paper evaluates three double-blind,
randomized controlled trials comparing the efficacy of NAC as an oral medication for reducing
the severity of OCD.
OBJECTIVE
The objective of this selective evidence based medicine review is to determine whether or not
“In adult patients with Obsessive Compulsive Disorder (OCD), is the amino acid N-Acetyl
Cysteine (NAC) effective in reducing severity of OCD?”
METHODS
Specific search criteria were used to obtain three studies for this review. The studies all
were randomized, double-blind, placebo controlled clinical trials that used non-pregnant adults
18-70 years old with OCD. Additional criteria included use of the Y-BOCS scale to measure
reduction in OCD after a trial of NAC. One of the studies selected patients with a Y-BOCS score
of >21 while another study selected patients that scored >16 on the Y-BOCS.2,8 The third study
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chose patients that scored >16 on the total Y-BOCS but also chose patients if they scored >10 for
the presence of only compulsions.1 All of the studies used a titrated dose of NAC, with two
studies reaching a daily dose of 3000mg, and one study reaching a daily dose of 2000mg.1,2,8 One
study did not allow patients to have previously taken any psychotropic medications six weeks
prior to the study. The other studies had more leniency with allowing stable medications to be
taken throughout the trial.1,2,8 One study also had patients taking fluvoxamine in both the
experimental and control groups during the course of the trial. 2 All three studies were doubleblind randomized control trials that used visual and taste matched placebos to the NAC. 1,2,8 They
all measured the reduction in severity of OCD using the Y-BOCS.
To obtain this data, the key words “Obsessive Compulsive Disorder” and “Nacetylcysteine” were used. All of the data sources were published in English and were found by
the author via PubMed-NCBI. Selection was based on clinical question relevance and whether
the outcomes presented in each study were patient oriented evidence that matters (POEMs).
Inclusion criteria for this review consisted of randomized controlled double-blind studies that
were published after 2013. Exclusion criteria for this review were patients under 18 years old or
pregnant.1,2,8 The studies used for this review presented the statistics for Control Event Rate
(CER), Experimental Event Rate (EER), Relative Benefit Increase (RBI), Absolute Benefit
Increase (ABI), and Number Needed to Treat (NNT). Additionally, a p-value of <0.05 was
considered statistically significant for the results of each trial. The demographics of each study
are presented in Table 1.
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Table 1 - Demographics & Characteristics of included studies
Study

Type
RCT

#
Pts
39

Age
(yrs)
1865

Costa,
2017 (1)

Paydray,
2016 (2)

RCT

46

1860

Sarris,
2015 (8)

RCT

35

1870

Inclusion Criteria

Exclusion Criteria

W/D

Intervention

Patients with OCD
diagnosis, based on the
Diagnostic and Statistical
Manual-IV (DSM-IV),
who failed to respond to
>1 previous treatment and
had a total Y-BOCS >16,
or >12 on the
compulsions Y-BOCS
scale. Other medications
such as mood stabilizers,
stimulants, sedatives, and
hypnotics were allowed if
they were stable for 1
month. Antipsychotics
and clomipramine were
allowed if they were
prescribed 2 months prior
and stable one month.
Patients who met the
DSM-IV Text Revision
criteria of mod-severe
OCD, scoring >21 on YBOCS who did not
receive psychotropic
medications 6wks prior to
study.

Presence of any
psychotic disorder, liver
disease, asthma,
previous psychosurgery,
current drug
abuse/dependence,
suicide risk,
comorbidities
preventing use of
protocol medications,
previous exposure to
NAC, pregnancy,
lactation, or women
without reliable birth
control methods.

4

NAC,
1200mg/day
x1wk,
2400mg/day
x1wk,
3000mg/day
x14wks.
Patients also
continued
regimen of
medications
prescribed
before the RCT.

Suicidal ideation,
seizures, substance
dependence, IQ<70,
comorbid DSM-IV axis
1 disorders,
neurological, cardiac,
renal, hepatic, or other
serious medical illness,
psychosurgery, head
trauma, pregnancy,
breastfeeding

2

NAC,
1000mg/day
x1wk,
2000mg/day x9
wks.
Patients also
had
fluvoxamine
100mg/day
x4wks,
200mg/day
x6wks.

Patients who fulfill the
DSM-IV text revision
criteria, scoring >16,
without any treatment for
the past 4 weeks if this is
the 2nd medication they
are trying, or 12 weeks if
this is the 1st medication
they are trying. Females
were required to use
effective contraception if
of childbearing age and
sexually active.

Current engagement in a
psychological program,
a clinically unstable
medical disorder,
bipolar I disorder,
epilepsy, schizophrenia,
asthma, or recent
gastrointestinal ulcers,
pregnancy,
breastfeeding,
consumption of >250mg
NAC, 100 mg selenium,
or 500 IU Vitamin E.

1

NAC,
1000mg/day
x1wk,
2000mg/day
x1wk,
3000mg/day
x14wks.
Patients also
continued
regimen of
medications
prescribed
before the RCT.
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OUTCOMES MEASURED
The outcome measured, a reduction in the severity of OCD, was a POEM. It was
obtained using the self-reported Y-BOCS. The exam begins with a 67 part questionnaire that
patients fill out. Based on the responses from the questionnaire, the interviewer creates a list of
target symptoms.10 The interviewer then uses the target symptoms to ask 19 additional interviewstyle questions, where the patient rates his/her symptoms on a scale of 0-4.10,11 The higher the
number, the higher the severity. Based on the patient’s responses, questions 1-10 are added
together for a total Y-BOCS score.10,11 Questions 11-19 are excluded from the total score
because they are considered investigational.11
RESULTS
In the study conducted by Costa DLC, Diniz JB, Requena G, et al., there were 39 patients
age 18-65 originally included in the trial, with 22 allocated to the control group, and 17 allocated
to the experimental group.1 A modified intention-to-treat analysis was conducted because two
patients (one from the placebo group and one from the experimental group) dropped out before
week three, which were excluded from the analysis.1 Two other patients from the placebo group
dropped out before the end of the trial, but their missing data was imputed using the last
observation carried forward.1 The dropout rate between the two groups was not significant,
indicating congruence between the groups throughout the trial (NAC= 1 of 17, placebo= 3 of 22;
p=0.43).1 This study is generalized to male and non-pregnant female adults but limited to
patients with treatment-resistant OCD. The experimental group received NAC 1200mg/day for
one week, 2400mg/day for the next week, and 3000mg/day for the following 14 weeks.1 The
experimental group was given a taste and visually matched placebo. All patients in the study
were also taking an SSRI that they were stable on before starting the study; mood stabilizers,
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stimulants, sedatives, and hypnotics had to be stable for at least one month; antipsychotics and
clomipramine had to be stable for at least two months.1 Y-BOCS were administered every week
for the first three weeks and then every two weeks until the end of the 16 week trial.1
Furthermore, the data gathered in the study was provided as dichotomous data, allowing
for the calculations demonstrated in Table 2 below. Successful reduction in symptoms was
considered a reduction in >25% in Y-BOCS score from week zero to week sixteen.1 From the
beginning to end of the trial, the NAC group had an average reduction of 4.3 points (25.6+4.4 to
21.3+8.1) while the placebo group had an average reduction of 3 points (24.8+3.8 to 21.8+6.0).1
In the experimental group, 6 of 16 patients met the criteria for successful reduction in the YBOCS score, while 5 of 19 patients in the placebo group met the criteria for a successful
reduction in the Y-BOCS score (P=0.40).1 For every eight patients that are treated with NAC,
one patient will have a reduction of >25% on the Y-BOCS. This trial had a small treatment
effect.
Table 2: Efficacy of NAC in Reducing Severity of OCD Compared to Placebo
Study
Costa1
Paydray2
Sarris8

CER
0.26
0.36
0.27

EER
0.40
0.50
0.20

RBI
0.54
0.39
0.54

ABI
0.14
0.14
-0.07

NNT
8
8
-14

In the study led by Paydray K, Akamaloo A, Ahmadipour A, et al., 22 patients were
included in each the experimental and control group with ages ranging from 18-60.2 The data
were presented as intention-to-treat analysis, meaning each subject was kept in the group to
which he/she was originally assigned. The difference between Y-BOCS scores in each group did
not differ significantly (NAC= 27.04+4.39, placebo= 25.81+3.83; P=0.32).2 This study was
generalized to male and non-pregnant female adults with OCD. The experimental group received
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1000mg/day of NAC for the first week, and 2000mg/day for the remaining nine weeks. 2 The
control group was given a placebo in place of the NAC for the same length of time.2 Both groups
were also given 100mg/day of fluvoxamine for the first four weeks and 200mg/day for the
remaining six weeks.2 Patients included in this study did not receive psychotropic medications
six weeks prior to starting the NAC or placebo and fluvoxamine. 2
The Y-BOCS was administered at week zero, four, eight, and ten.2 Similar to the first
study, a reduction in Y-BOCS score >25% was considered successful treatment.2 In the results of
the trial, both groups had patients with reduced severity of OCD. Of the 22 patients in the NAC
group, 11 achieved successful treatment outcomes while 8 of 22 within the placebo group had
successful treatment.2 Comparing these results, there was no significant difference in reduction
of symptoms (P=0.54).2 The data was presented as dichotomous data, which allowed for the
calculations shown in Table 2. This trial had a small treatment effect. For every eight patients
that are treated with NAC, one patient will have a reduction of >25% on the Y-BOCS.
The final study from Sarris J, Oliver G, Camfield DA, et al. included 20 patients in the
experimental group and fifteen patients in the placebo group, ranging from 18-70 years old.8 This
study was generalized to male and non-pregnant female adults and limited to patients with OCD.
In this study, the experimental group received 1000mg/day for the first week, 2000mg/day the
second week, and 3000mg/day for the following 14 weeks.8 Patients were allowed to remain on
prior medications if they were stabilized for at least four weeks before starting the trial or 12
weeks if this was the patient’s first OCD treatment.8 Compliance was measured by how
consistently the patient took the NAC; a consumption rate of 75% or greater was considered
compliant.8 The Y-BOCS was administered at baseline and every four weeks until the end of the
trial at week 16. Treatment was considered successful if there was a decrease in Y-BOCS score
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of >35%.8 Over the course of the trial, there were more patients by percentage in the control
group that had Y-BOCS symptom reduction. Collectively the NAC group had an average
reduction of 5.42 points (25.65+5.06 to 20.23+8.86).8 The placebo group had an average
reduction of 4.50 points (25.87+4.70 to 20.82+8.29).8 Of the 20 patients in the NAC group, 4
patients were considered responders to treatment; of the 15 patients in the placebo group, 4
patients were considered responders (P=0.15).8 The data was presented in dichotomous form,
allowing for the calculations presented in Table 2. This trial had a very poor treatment effect. For
every 14 patients treated with NAC, its use will have a negative effect on one patient in reducing
the severity of OCD.
DISCUSSION
When comparing the total point decrease among the experimental groups and control
groups, the experimental group had a greater average point reduction in all three trials. However,
the difference between the experimental and control groups based on p-values was calculated to
be insignificant each time. Placebo groups should not have had a significant reduction in YBOCS scores alongside the NAC group. In one trial, there were actually more patients in the
control group than the NAC group that had decreased Y-BOCS scores.8 These results make the
effectiveness of NAC in patients with OCD difficult to assess.
Aside from its possible role in reducing OCD severity, NAC is most commonly known
for its use in reversing acetaminophen toxicity. With its role in the glutaminergic system and its
antioxidant effects, it has been shown to be beneficial in chronic diseases such as chronic
obstructive pulmonary disease, contrast induced nephropathy, idiopathic pulmonary fibrosis, and
influenza.12 More importantly, there has been efficacy among patients taking NAC with mental
health disorders.12 In studies of patients with schizophrenia, bipolar disorder, and nail-biting,
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there was a reduction of disease specific symptoms. However, the schizophrenia, bipolar
disorder, and nail-biting studies all lasted 24 weeks, whereas two trials reviewed in this paper
lasted 16 weeks and one trial lasted ten weeks.1,2,8,12 An extended study may have shown more
beneficial outcomes for patients with OCD, as NAC demonstrated benefit in other mental
disorders when used for a longer time period. A longer duration may have also decreased the
number of responders among the placebo groups.
In addition to duration of trials, there were other limitations. Each of the studies used
sample sizes of less than 50 patients.1,2,8 Once patients were split in half for an experimental
group and control group, 25 or less patients used NAC during each of the trials. While the
studies were double-blind and placebo controlled, limited sample sizes can increase error margin.
Also, compliance with medications could have influenced the results. One trial reported a
compliance threshold of 75% of pills taken throughout the 16 week study.8 This means that
patients would still be considered compliant even if they missed up to four weeks of treatment.
The other trials did not state compliance thresholds that patients were required to meet.
In addition, two of the studies allowed patients to continue taking psychotropic
medications such as SSRIs and antipsychotics.1,8 While those medications were stabilized prior
to initiating the trial of NAC, drug interactions were not specifically studied in these trials.
Previous medications the patients were taking could have modified the effect of NAC.
In regard to NAC’s tolerability, very few adverse outcomes were reported throughout the
three trials. The only significant adverse outcomes were stomach/abdominal pain and
heartburn.1,8 Other adverse effects that were reported occurred in both the experimental and
placebo groups thus making them nonsignificant. NAC’s tolerability, in addition to its wide
availability over the counter and relatively cheap cost make its use more desirable. NAC can be
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found for around $10-20 for a 120 count of 600mg tablets.13 However, these benefits do not
prove useful for OCD patients when the data suggests it is not effective in reducing OCD
symptom severity when compared to a placebo. Further studies need to be conducted to evaluate
reduction in Y-BOCS score among patients taking NAC.
CONCLUSION
The evidence for whether the amino acid NAC is effective in reducing the severity of
OCD in adults is inconclusive. Among the three RCTs used in this review, it was found that
patients’ Y-BOCS scores decreased. However, these results are insignificant because the placebo
group in each trial also had a decrease in Y-BOCS score. Two trials needed to treat eight patients
before seeing benefit in one patient. The third trial, based on the percentage of patients in the
NAC and control groups that met criteria for OCD symptom severity, indicated that one patient
would have a negative effect for every 14 patients that were treated with NAC.
It would be worthwhile to investigate the use of NAC for OCD further due to its
reduction in symptoms that occurred, benefits in other mental health disorders, its tolerability,
and minimal cost. Future studies could include longer trial duration, more participants, or higher
dosages of NAC. Additionally, exploring NAC as monotherapy or dual therapy with one
consistent medication may provide significant results. This would eliminate one of the
limitations of the study that allowed patients to take other medications, possibly decreasing the
efficacy of NAC.
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